ICON plc Sets July 31, 2026 AGM and Seeks Expanded Capital Authorities
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
The latest update is out from Icon ( (ICLR) ).
ICON plc, the Irish-headquartered clinical research organization listed on Nasdaq, has filed a June 2026 Form 6-K with the U.S. Securities and Exchange Commission, furnishing shareholders with its consolidated IFRS financial statements, IFRS annual report and Form 20-F for the year ended 31 December 2025. The filing also includes the shareholder letter and formal notice of the company’s 2026 Annual General Meeting, alongside the proxy voting card to support investor participation.
In a letter dated 26 June 2026, ICON called shareholders to its AGM scheduled for 31 July 2026 at its Dublin headquarters, where all ten directors will stand for election or re-election, including new board members Kevin Egan and Jeff Elliott, who joined on 1 June 2026 and were appointed to the Audit Committee. Shareholders will be asked to approve the 2025 audited accounts, authorize the board to issue up to 20% new shares and disapply pre-emption rights for up to 20% in total under specified conditions, renew authority for buy-backs of up to 10% of outstanding shares, and set parameters for reissuing treasury shares, measures that collectively maintain capital-raising flexibility and anti-dilution protections within Irish law and Nasdaq norms.
The resolutions also empower the board, via its Audit Committee, to set auditor remuneration and renew buy-back and treasury share reissuance authorities through to the earlier of the next AGM or 30 January 2028. ICON reiterated that, as a foreign private issuer, it is not required to hold a “say on pay” vote, directing shareholders instead to its 2025 IFRS Annual Report and Form 20-F for detailed disclosure on executive compensation, highlighting a governance framework aligned with both Irish corporate requirements and U.S. market expectations.
The most recent analyst rating on (ICLR) stock is a Buy
with a $190.00 price target.
To see the full list of analyst forecasts on Icon stock,
see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Neutral.
ICLR scores in the upper-middle range primarily due to strong technical momentum and a steady earnings-call outlook supported by robust bookings and reiterated 2026 guidance. The score is held back by weaker recent financial performance (notably margin compression and softer cash-flow trends) and a relatively high P/E with no dividend yield.
To see Spark’s full report on ICLR stock,
click here.
More about Icon
ICON plc is a Dublin-headquartered clinical research organization that provides outsourced development and commercialization services to pharmaceutical, biotechnology and medical device companies. Listed on Nasdaq and reporting under IFRS and Form 20-F, the company focuses on running global clinical trials and related services for life sciences clients, positioning itself as a key player in the contract research sector.
Average Trading Volume: 1,194,608
Technical Sentiment Signal: Hold
Current Market Cap: $12.32B
See more insights into ICLR stock on TipRanks’ Stock Analysis page.
